Spire Wealth Management Neurocrine Biosciences Inc Transaction History

Spire Wealth Management

$2.95 Billion
Q3 2024

A detailed history of Spire Wealth Management transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Spire Wealth Management holds 198 shares of NBIX stock, worth $26,813. This represents 0.0% of its overall portfolio holdings.

Number of Shares

198

Previous 198 -0.0%

Holding current value

$26,813

Previous $27,000 18.52%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$130.86 - $143.19 $8,113 - $8,877	62 Added 45.59%	198 $27,000
Q1 2024 Apr 24, 2024	SELL	$130.4 - $143.74 $2,216 - $2,443	-17 Reduced 11.11%	136 $18,000
Q4 2023 Feb 06, 2024	BUY	$106.07 - $132.76 $8,485 - $10,620	80 Added 109.59%	153 $20,000
Q3 2023 Nov 08, 2023	SELL	$94.02 - $117.1 $29,710 - $37,003	-316 Reduced 81.23%	73 $8,000
Q2 2023 Aug 09, 2023	BUY	$89.53 - $104.87 $895 - $1,048	10 Added 2.64%	389 $36,000
Q1 2023 May 09, 2023	BUY	$94.11 - $123.02 $23,903 - $31,247	254 Added 203.2%	379 $38,000
Q4 2022 Feb 03, 2023	BUY	$106.72 - $127.06 $1,600 - $1,905	15 Added 13.64%	125 $15,000
Q3 2022 Nov 07, 2022	SELL	$92.03 - $107.81 $460 - $539	-5 Reduced 4.35%	110 $12,000
Q2 2022 Jul 22, 2022	BUY	$75.79 - $100.07 $378 - $500	5 Added 4.55%	115 $11,000
Q1 2022 Apr 18, 2022	SELL	$72.45 - $94.81 $1,231 - $1,611	-17 Reduced 13.39%	110 $10,000
Q4 2021 Jan 14, 2022	SELL	$79.65 - $106.22 $14,575 - $19,438	-183 Reduced 59.03%	127 $11,000
Q2 2021 Jul 26, 2021	SELL	$89.43 - $102.27 $25,308 - $28,942	-283 Reduced 47.72%	310 $30,000
Q1 2021 May 21, 2021	BUY	$87.57 - $119.4 $51,929 - $70,804	593 New	593 $58,000

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Spire Wealth Management with notifications on news.

Account

Spire Wealth Management Neurocrine Biosciences Inc Transaction History